Claudin 18.2 Targeting: A Pan-Cancer Perspective

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Claudin 18.2 (CLDN18.2) is a specific target primarily found on gastric mucosal cells.
• Its expression is observed in various cancers, including gastric, gastroesophageal junction (GEJ), pancreatic, and ovarian cancers.
• CLDN18.2 expression can vary within tumors and change during treatment.

Purpose of the Study:

• To review CLDN18.2 expression patterns in different cancers.
• To summarize clinical trial data for zolbetuximab and other CLDN18.2-targeted therapies.
• To highlight the importance of biomarker-driven patient selection for CLDN18.2-targeted treatments.

Main Methods:

• Review of existing literature on CLDN18.2 expression.
• Analysis of clinical trial outcomes for zolbetuximab and other CLDN18.2-directed agents.
• Assessment of immunohistochemistry methods for CLDN18.2 detection.

Main Results:

• Zolbetuximab, an anti-CLDN18.2 antibody, is FDA-approved for gastric/GEJ cancers in combination therapy.
• Other CLDN18.2-targeted therapies like antibody-drug conjugates and CAR-T cells are in clinical development.
• Despite CLDN18.2 expression on gastric mucosa, therapies have shown tolerable safety profiles with anti-emetic support.

Conclusions:

• Biomarker-driven approaches are crucial for selecting patients in CLDN18.2-targeted therapy trials.
• Understanding CLDN18.2 heterogeneity is key for effective therapeutic strategies.
• Continued research into CLDN18.2 expression and targeted therapies holds promise for cancer treatment.